A JAK2 mutation in myeloproliferative disorders: Pathogenesis and therapeutic and scientific prospects

Trends in Molecular Medicine

Volumn 11, Issue 12, 2005, Pages 546-554

  James, Chloé ^a   Ugo, Valérie ^a,b   Casadevall, Nicole ^a,c   Constantinescu, Stefan N ^d   Vainchenker, William ^a  

^a INSERM   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

^c HÔTEL DIEU   (France)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; JANUS KINASE 2; MESSENGER RNA; NILOTINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

CLINICAL FEATURE; CLINICAL TRIAL; ENZYME ACTIVATION; GENE EXPRESSION; GENE MUTATION; HUMAN; MOLECULAR CLONING; MYELOID LEUKEMIA; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; POLYCYTHEMIA VERA; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; THROMBOCYTHEMIA;

GENE COMPONENTS; HUMANS; JANUS KINASE 2; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION;

EID: 28244496095     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2005.10.003     Document Type: Review

References (69)

1. W. Dameshek Some speculations on the myeloproliferative syndromes Blood 6 1951 372 375
2. J.L. Spivak The chronic myeloproliferative disorders: clonality and clinical heterogeneity Semin. Hematol. 41 2, Suppl. 3 2004 1 5
3. J.W. Vardiman The World Health Organization (WHO) classification of the myeloid neoplasms Blood 100 2002 2292 2302
4. R.T. Silver Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera Leukemia 17 2003 1186 1187
5. R. Marchioli Vascular and neoplastic risk in a large cohort of patients with polycythemia vera J. Clin. Oncol. 23 2005 2224 2232
6. M. Ruggeri The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis Ann. Intern. Med. 139 2003 470 475
7. J. Cools A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome N. Engl. J. Med. 348 2003 1201 1214
8. C. James A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 2005 1144 1148
9. R. Kralovics A gain-of-function mutation of JAK2 in myeloproliferative disorders N. Engl. J. Med. 352 2005 1779 1790
10. R.L. Levine Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 2005 387 397
11. E.J. Baxter Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 2005 1054 1061
12. R. Zhao Identification of an acquired JAK2 mutation in polycythemia vera J. Biol. Chem. 280 2005 22788 22792
13. R. Ren Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia Nat. Rev. Cancer 5 2005 172 183
14. J. Gotlib The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management Blood 103 2004 2879 2891
15. A. Tefferi, and A. Pardanani Clinical, genetic, and therapeutic insights into systemic mast cell disease Curr. Opin. Hematol. 11 2004 58 64
16. H.L. Pahl Towards a molecular understanding of polycythemia rubra vera Eur. J. Biochem. 267 2000 3395 3401
17. F.A. Asimakopoulos, and A.R. Green Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders Br. J. Haematol. 95 1996 219 226
18. A.J. Bench Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignancies Br. J. Haematol. 127 2004 509 518
19. R. Kralovics Familial polycythemia vera: mode of inheritance, clonality, and genetic analysis of candidate genes and chromosomal regions Blood 94 1994 113a
20. R. Kralovics Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera Exp. Hematol. 30 2002 229 236
21. V. Najfeld Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected Br. J. Haematol. 119 2002 558 566
22. U. Bacher Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders Cancer Genet. Cytogenet. 160 2005 179 183
23. R. Kralovics Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders Blood 102 2003 1869 1871
24. J.F. Prchal, and A.A. Axelrad Letter: Bone-marrow responses in polycythemia vera N. Engl. J. Med. 290 1974 1382
25. J.J. Michiels, and E. Juvonen Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group Semin. Thromb. Hemost. 23 1997 339 347
26. H.L. Pahl PRV-1 mRNA expression and other molecular markers in polycythemia rubra vera Curr. Hematol. Rep. 2 2003 231 236
27. A.L. Taksin Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L Blood 93 1999 125 139
28. A.A. Axelrad Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia Blood 96 2000 3310 3321
29. E. Juvonen Megakaryocyte colony formation in chronic myeloid leukemia and myelofibrosis Leuk. Res. 12 1988 751 756
30. J.P. Le Couedic Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies Blood 87 1996 1502 1511
31. Y. Li Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders Br. J. Haematol. 92 1996 60 66
32. J.W. Adamson Polycythemia vera: stem-cell and probable clonal origin of the disease N. Engl. J. Med. 295 1976 913 916
33. W.H. Raskind Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia J. Clin. Invest. 75 1985 1388 1390
34. P.J. Fialkow Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell Blood 58 1981 916 919
35. N. el-Kassar Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets Blood 89 1997 128 134
36. C.N. Harrison A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications Blood 93 1999 417 424
37. A.I. Schafer Thrombocytosis N. Engl. J. Med. 350 2004 1211 1219
38. S. Temerinac Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera Blood 95 2000 2569 2576
39. S. Klippel Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis Blood 102 2003 3569 3574
40. L. Teofili Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia J. Clin. Oncol. 20 2002 4249 4254
41. E. Liu Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin Blood 101 2003 3294 3301
42. D.F. Stroncek CD177: a member of the Ly-6 gene superfamily involved with neutrophil proliferation and polycythemia vera J. Transl. Med. 2 2004 8
43. F. Passamonti Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders Br. J. Haematol. 126 2004 650 656
44. D.P. Steensma, and A. Tefferi Cytogenetic and molecular genetic aspects of essential thrombocythemia Acta Haematol. 108 2002 55 65
45. A.R. Moliterno Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera N. Engl. J. Med. 338 1998 572 580
46. A.R. Moliterno, and J.L. Spivak Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera Blood 94 1999 2555 2561
47. E. Anastasiadou, and J. Schwaller Role of constitutively activated protein tyrosine kinases in malignant myeloproliferative disorders: an update Curr. Opin. Hematol. 10 2003 40 48
48. L. Oehler Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro Blood 102 2003 2240 2242
49. M. Silva Expression of Bcl-x in erythroid precursors from patients with polycythemia vera N. Engl. J. Med. 338 1998 564 571
50. S. Roder STAT3 is constitutively active in some patients with Polycythemia rubra vera Exp. Hematol. 29 2001 694 702
51. C. Dai Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB Exp. Hematol. 33 2005 152 158
52. L.J. Huang The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor Mol. Cell 8 2001 1327 1338
53. Y. Royer Janus kinases affect thrombopoietin receptor cell surface localization and stability J. Biol. Chem. 280 2005 27251 27261
54. V. Ugo Multiple signaling pathways are involved in erythropoietin- independent differentiation of erythroid progenitors in polycythemia vera Exp. Hematol. 32 2004 179 187
55. E. Komura Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression Exp. Hematol. 31 2003 622 630
56. Levine, R.L. et al. (2005) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood DOI:10.1182/blood-2005-05-1898 (www.bloodjournal.org)
57. P. Saharinen Regulation of the Jak2 tyrosine kinase by its pseudokinase domain Mol. Cell. Biol. 20 2000 3387 3395
58. D.P. Steensma The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and the myelodysplastic syndrome Blood 106 2005 1207 1209
59. A.V. Jones Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders Blood 106 2005 2162 2168
60. Jelinek, J. et al. JAK2 mutation 1849G >T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood (in press)
61. P.S. Goerttler The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients Blood 106 2005 2862 2864
62. B.J. Druker STI571 (Gleevec) as a paradigm for cancer therapy Trends Mol. Med. 8 4 Suppl 2002 S14 S18
63. G.W. Krystal Imatinib mesylate (STI571) for myeloid malignancies other than CML Leuk. Res. 28 Suppl 1 2004 S53 S59
64. J. Cortes, and H. Kantarjian Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders Cancer 100 2004 2064 2078
65. K. Cohen-Solal High-level expression of Mpl in platelets and megakaryocytes is independent of thrombopoietin Blood 93 1999 2859 2866
66. A.M. Vannucchi A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis Blood 105 2005 3493 3501
67. F. Dong Identification of a nonsense mutation in the granulocyte-colony- stimulating factor receptor in severe congenital neutropenia Proc. Natl. Acad. Sci. U. S. A. 91 1994 4480 4484
68. B.J. Huntly MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors Cancer Cell 6 2004 587 596
69. K. Kaushansky On the molecular origins of the chronic myeloproliferative disorders: it all makes sense Blood 105 2005 4187 4190